Rossi Antonio, Maione Paolo, Colantuoni Giuseppe, Gaizo Filomena Del, Guerriero Ciro, Nicolella Dario, Ferrara Carmine, Gridelli Cesare
Unità Operativa di Oncologia Medica, Azienda Ospedaliera "S.G. Moscati", Contrada Amoretta, Città Ospedaliera, 83100 Avellino, Italy.
Crit Rev Oncol Hematol. 2005 Dec;56(3):311-20. doi: 10.1016/j.critrevonc.2005.04.007. Epub 2005 Jun 22.
Lung cancer remains the leading cause of cancer-related deaths in the world. At present, the only high rate of cure therapy is surgical resection at early stage of disease. Early detection could potentially decrease lung cancer mortality suggesting that this cancer should be a good candidate for screening. Results of trials involving chest X-ray, sputum cytology and low-dose computed tomography (CT) are discussed here. The latter tool offers advantages over chest X-ray, but final results from controlled well conducted trials are necessary before the real utility of CT mass screening can be determined. Further approaches to secondary prevention such as screening with positron emission tomography (PET), autofluorescence bronchoscopy and biomarkers hold great promise for the future.
肺癌仍然是全球癌症相关死亡的主要原因。目前,唯一治愈率高的治疗方法是疾病早期的手术切除。早期检测有可能降低肺癌死亡率,这表明这种癌症应该是筛查的理想对象。本文讨论了涉及胸部X光、痰细胞学和低剂量计算机断层扫描(CT)的试验结果。后一种工具比胸部X光有优势,但在确定CT大规模筛查的实际效用之前,需要有精心设计的对照试验的最终结果。正电子发射断层扫描(PET)、自发荧光支气管镜检查和生物标志物等二级预防的进一步方法在未来很有前景。